ClearSign Technologies Corp (CLIR): Nasdaq/NYSE listing notice — ClearSign receives Nasdaq minimum bid price deficiency notice; 180 days to cure

ClearSign Technologies Corp

Received Nasdaq deficiency notice on Nov 1, 2022 for failing to maintain $1 minimum bid price (Rule 5550(a)(2)).
Has 180 calendar days until May 1, 2023 to regain compliance with bid price ≥$1 for 10 consecutive business days.
If not cured, may seek additional 180-day extension if it meets other Nasdaq Capital Market listing standards.
No immediate delisting; company monitoring options but no assurance of regaining compliance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

ClearSign Technologies Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

November 1, 2022, ClearSign Technologies Corporation (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days beginning on September 20, 2022 and ending on October 31, 2022, the Company no longer meets the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been pr

View on SEC.gov

18 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

ClearSign Technologies Corp filing history →

Source: SEC EDGAR

accession 0001104659-22-114927

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.